Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Management reaffirmed that the soquelitinib Phase II atopic dermatitis trial will begin in early Q1 2026, enrolling approximately 200 patients across 70 global sites and including those who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback